Loading
A phase 2 trial of UGT1A1 genotyping before irinotecan in Colorectal cancer, run by Shanghai Changzheng Hospital, with a status the registry has not verified recently.
High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 is a phase 2 interventional study registered as NCT03329183 by Shanghai Changzheng Hospital, with 90 participants planned, started 2019-03 and due to reach its primary completion in 2019-03. Interventions recorded: Irinotecan. Conditions recorded: Colorectal Cancer.
Linked to the technology UGT1A1 genotyping before irinotecan because the registry's title names it ("ugt1a1 6") and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares UGT1A1, UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares UGT1A1, UGT1A1 genotyping before irinotecan, Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan) and the tag pipeline.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/